Hyperplasia clinical trials

The registry lists 76 studies for Hyperplasia across more than 10 countries. 9 are recruiting or about to start. 32 of them are mainly about Hyperplasia (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-23.

Get an email when these change. Save the Hyperplasia studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 43
Status unknown: 12
Recruiting: 5
Terminated: 4
Active, not recruiting: 4
Withdrawn: 4

Phase

Phase 2: 14
Phase 3: 10
Phase 1: 5
Phase 4: 5
Early Phase 1: 1

Where

United States: 30
China: 6
Canada: 6
Taiwan: 4
Egypt: 3
France: 3

Who runs them

National Cancer Institute (NCI) (4) · Shandong University (2) · Mansoura University (2) · National Taiwan University Hospital (2) · Anesiva, Inc. (2) · S.L.A. Pharma AG (2) · Proteocyte Diagnostics Inc. (2) · Northwestern University (2)

What is being tested here

Drugs under test in Hyperplasia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Tirzepatide	1	0	1
Eicosapentaenoic Acid	0	2	3
Broccoli Sprout/Broccoli Seed Extract Supplement	0	0	2
Edifoligide	0	1	2
Metformin	0	0	1
Hydrocortisone	0	0	1
Cholecalciferol	0	0	1
Dexpanthenol	0	0	1
Tadalafil	0	1	1
Pegvisomant	0	1	1

Coming up

1phase 3 study under way

1study finishes main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The study

Dec 2026Treatment of Sebaceous Hyperplasia With PDL and Nd:YAG Versus Erbium:YAG: A Randomized Controlled Trial · Northwestern University

Who these studies take

Of the 5 Hyperplasia studies recruiting now, 2 (40%) set no upper age limit and 2 (40%) stop at 75 or younger. 2 (40%) take children under 18. 1 (20%) are for women only and 1 (20%) for men only; 1 (20%) take healthy volunteers.

Recruiting studies that take each age, of 5
Age	Women	Men
10	1 (20%)	1 (20%)
18	3 (60%)	3 (60%)
30	3 (60%)	3 (60%)
40	3 (60%)	3 (60%)
50	3 (60%)	3 (60%)
65	2 (40%)	3 (60%)
75	2 (40%)	3 (60%)
85	2 (40%)	3 (60%)

Across all 76 studies, recruiting or not: 21% stop at 75 or younger and 16% at 65; 21% take children; 18% are for women only and 21% for men only; 22% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hyperplasia studies take

Of 14 interventional studies with no phase under Hyperplasia, half reached primary completion within 23 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Interventional, no phase	23 mo11–35 · 14 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 76. Browse all 76 → or search them.